Relmada Therapeutics (RLMD) Asset Utilization Ratio (2013)

Relmada Therapeutics (RLMD) reported Asset Utilization Ratio of 0.3 for Q4 2013, down 27.88% quarter-over-quarter from 0.41 in Q3 2013.

Relmada Therapeutics (RLMD) Asset Utilization Ratio (2013) Analysis & Trends

Relmada Therapeutics (RLMD) has 1 years of Asset Utilization Ratio data on file, last reported at 0.3 in Q4 2013.

Asset Utilization Ratio for Q4 2013 came in at 0.3, changed N/A year-over-year; the trailing twelve-month figure through Nov 2013 was 0.3 (changed N/A YoY), and the FY2013 annual result was 0.27, changed N/A from the prior year.
Asset Utilization Ratio declined to 0.3 in Q4 2013 per RLMD's latest filing, from 0.41 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.89 in Q2 2013 and troughed at 0.3 in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	0.55
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.60
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	1,422.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.47
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Relmada Therapeutics	581.07 Mn	581.07 Mn	-	-

Download Data